# Transferable priority vouchers for first-in-class drugs, with price conditions

Source: https://onco.cc/ideas/idea-fund-conditional-transferable-voucher/  
OnCo record `idea-fund-conditional-transferable-voucher` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Reward companies that deliver a genuinely new kind of cancer drug with a sellable voucher for faster review of another product, but only if they agree to fair pricing and global access.

## Summary

Extend the US priority review voucher model (rare paediatric disease, tropical disease) to oncology first-in-class approvals that show substantial survival benefit, with two conditions attached: a price commitment (for example launch price below a value-based threshold set by an independent body) and a global access plan (tiered pricing or licensing to the Medicines Patent Pool for low- and middle-income countries). The voucher is transferable and has sold for around $100 million historically, so the reward is real but costs the public little. Regulators would need statutory authority; a pilot could run through an existing programme's criteria.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A conditional oncology voucher increases the number of first-in-class oncology approvals meeting the survival threshold per decade and results in launch prices at least 20% lower for voucher-qualified drugs than for comparable unconditioned launches.
- Rationale: Rare paediatric vouchers have measurably increased paediatric rare disease activity, though without price conditions; conditional rewards are standard in public procurement. Vouchers reward the outcome (approval) rather than inputs and are cheap for governments.
- Proposed test: Model uptake with industry through a regulator-convened consultation, then legislate a five-year sunset pilot and compare first-in-class filings and launch prices before and after.
- Maturity: speculative
- Actor: regulator

## Sources

- Medicines Patent Pool: https://medicinespatentpool.org/

## Connected records

- ideas: [A Health Impact Fund pilot that pays for measured health gain instead of price](https://onco.cc/ideas/idea-fund-health-impact-fund-oncology/), [Patent term extension scaled to proven survival gain](https://onco.cc/ideas/idea-fund-value-based-patent-extension/), [University licences with royalties indexed to benefit and global access](https://onco.cc/ideas/idea-fund-global-access-licensing-royalties/)
- terms: [Accelerated approval](https://onco.cc/terms/accelerated-approval/), [Breakthrough Therapy / Priority Review / Priority Voucher](https://onco.cc/terms/breakthrough-designation/)
- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-conditional-transferable-voucher.json